Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes

Arthritis Research and Therapy

Volumn 15, Issue 1, 2013, Pages

  Choe, Jung Yoon ^a   Park, Ki Yeun ^a   Park, Sung Hoon ^a   Lee, Sang Il ^b   Kim, Seong Kyu ^a  

^a Catholic University of Daegu   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE 2; MESSENGER RNA; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; CALCINEURIN INHIBITOR; SOCS3 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE EROSION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG POTENCY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MALE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; UPREGULATION; WESTERN BLOTTING; ANIMAL; ARTHRITIS, EXPERIMENTAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; SYNOVIUM; TRANSGENIC MOUSE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CALCINEURIN INHIBITORS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SYNOVIAL MEMBRANE; TACROLIMUS;

EID: 84876019491     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4162     Document Type: Article

References (33)

1. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 1999, 163:434-442.
2. Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, Tak PP, Haynes DR. Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002, 61:1047-1054. 10.1136/ard.61.12.1047, 1753975, 12429533.
3. Ainola M, Mandelin J, Liljeström M, Konttinen YT, Salo J. Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. Clin Exp Rheumatol 2008, 26:240-246.
4. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology (Oxford) 2008, 47:1635-1640.
5. Tunyogi-Csapo M, Kis-Toth K, Radacs M, Farkas B, Jacobs JJ, Finnegan A, Mikecz K, Glant TT. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. Arthritis Rheum 2008, 58:2397-2408. 10.1002/art.23653, 18668542.
6. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther 2005, 7:100-110. 10.1186/ar1741, 1174965, 15899058.
7. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000, 19:2548-2556. 10.1038/sj.onc.1203551, 10851053.
8. Mori T, Miyamoto T, Yoshida H, Asakawa M, Kawasumi M, Kobayashi T, Morioka H, Chiba K, Toyama Y, Yoshimura A. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 2011, 23:701-712. 10.1093/intimm/dxr077, 21937456.
9. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 1999, 274:19301-19308. 10.1074/jbc.274.27.19301, 10383440.
10. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, Komiya S, Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yoshimura A. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001, 108:1781-1788. 209467, 11748261.
11. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003, 63:1247-1297. 10.2165/00003495-200363120-00006, 12790696.
12. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol 2003, 30:2193-2200.
13. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S. Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflamm Res 2004, 53:544-550. 10.1007/s00011-004-1294-9, 15597149.
14. Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem 2004, 279:13984-13992. 10.1074/jbc.M213067200, 14722106.
15. Miyazaki M, Fujikawa Y, Takita C, Tsumura H. Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis. Clin Rheumatol 2007, 26:231-239.
16. Spolidorio LC, Nassar PO, Nassar CA, Spolidorio DM, Muscará MN. Conversion of immunosuppressive monotherapy from cyclosporin A to tacrolimus reverses bone loss in rats. Calcif Tissue Int 2007, 81:114-123. 10.1007/s00223-007-9040-2, 17612778.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
18. Pettit AR, Ji H, von Stechow D, Müller R, Goldring SR, Choi Y, Benoist C, Gravallese EM. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699. 10.1016/S0002-9440(10)63016-7, 1867076, 11696430.
19. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602. 10.1073/pnas.95.7.3597, 19881, 9520411.
20. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995, 14:2816-2826. 398400, 7796808.
21. Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, Ihle JN, Rutschman R, Murray PJ. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 2003, 4:546-550. 10.1038/ni932, 12754506.
22. Andia DC, Nassar CA, Nassar PO, Guimarães MR, Cerri PS, Spolidorio LC. Treatment with tacrolimus enhances alveolar bone formation and decreases osteoclast number in the maxillae: a histomorphometric and ultrastructural study in rats. Histol Histopathol 2008, 23:1177-1184.
23. Igarashi K, Hirotani H, Woo JT, Stern PH. Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures. Bone 2004, 35:47-56. 10.1016/j.bone.2004.02.009, 15207740.
24. Kwak HB, Kim HS, Lee MS, Kim KJ, Choi EY, Choi MK, Kim JJ, Cho HJ, Kim JW, Bae JM, Kim YK, Park BH, Ha H, Chun CH, Oh J. Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression. Biol Pharm Bull 2009, 32:45-50. 10.1248/bpb.32.45, 19122279.
25. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D, Hilton DJ. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999, 98:597-608. 10.1016/S0092-8674(00)80047-1, 10490099.
26. Matsumoto A, Seki Y, Kubo M, Ohtsuka S, Suzuki A, Hayashi I, Tsuji K, Nakahata T, Okabe M, Yamada S, Yoshimura A. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 1999, 19:6396-6407. 84609, 10454585.
27. Edwards JR, Mundy GR. Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol 2011, 7:235-243. 10.1038/nrrheum.2011.23, 21386794.
28. Banerjee A, Banks AS, Nawijn MC, Chen XP, Rothman PB. Cutting edge: Suppressor of cytokine signaling 3 inhibits activation of NFATp. J Immunol 2002, 168:4277-4281.
29. Frobøse H, Rønn SG, Heding PE, Mendoza H, Cohen P, Mandrup-Poulsen T, Billestrup N. Suppressor of cytokine signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol 2006, 20:1587-1596.
30. May KP, West SG, McDermott MT, Huffer WE. The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum 1994, 37:201-206. 10.1002/art.1780370208, 8129775.
31. Revu S, Neregård P, af Klint E, Catrina AI. Methothrexate directly inhibits RANKL expression and osteoclast formation in very early arthritis [abstract]. Ann Rheum Dis 2010, 69:A23.
32. Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, Harrison K, Findlay DM, Zannettino AC. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003, 18:1088-1098. 10.1359/jbmr.2003.18.6.1088, 12817763.
33. Wei X, Zhang X, Zuscik MJ, Drissi MH, Schwarz EM, O'Keefe RJ. Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles. J Bone Miner Res 2005, 20:1136-1148. 10.1359/JBMR.050206, 15940366.